» Articles » PMID: 38977491

Applying Chemical Shift Images (in-phase/opposed Phased) for Differentiating Low-grade from High-grade Glioma and Comparison with Magnetic Resonance Spectroscopy

Overview
Specialty Radiology
Date 2024 Jul 8
PMID 38977491
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Grading gliomas is essential for treatment decisions and patient prognosis. In this study we evaluated the in-phase and out-of-phase sequences for distinguishing high-grade (HGG) from low-grade glioma (LGG) and the correlation with magnetic resonance spectroscopy (MRS) results.

Methods: This observational study comprised patients with brain tumors referred to our center for brain MRS. The gold standard for diagnosis was based on the World Health Organization (WHO) glioma classification. A standard tumor protocol was accomplished using a 1.5‑T MRS scanner. Before contrast medium administration, extra in- and out-phase sequences were acquired. Three 20-30-mm oval regions of interest (ROIs) were placed in the solid component and the signal loss ratio (SLR) was calculated with the following formula: SLR  = (SI  - SI ) / SI Correlations and comparisons between groups were made using the Pearson, chi-square and, independent samples t tests. Receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic performance. Statistical significance was set at p < 0.05.

Results: In total, 20 patients were included in the LGG and 13 were included in the HGG group. The mean SLR in the HGG and LGG groups was 3.66 ± 2.12 and 1.63 ± 1.86, respectively (p = 0.01). There was a statistically significant correlation between lipid lactate (0.48, p = 0.004) and free lipid (0.44, p = 0.009) concentrations on MRS with SLR.

Conclusions: The SLR is a simple, rapid, and noninvasive marker for differentiating between LGG and HGG. There is a significant correlation with both the concentration and presence of free lipid and lipid-lactate peaks in MRS.

References
1.
Hess K, Broglio K, Bondy M . Adult glioma incidence trends in the United States, 1977-2000. Cancer. 2004; 101(10):2293-9. DOI: 10.1002/cncr.20621. View

2.
Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

3.
Wen P, Packer R . The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications. Neuro Oncol. 2021; 23(8):1215-1217. PMC: 8328017. DOI: 10.1093/neuonc/noab120. View

4.
Sanai N, Berger M . Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008; 62(4):753-64. DOI: 10.1227/01.neu.0000318159.21731.cf. View

5.
Ostrom Q, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y . CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013; 15 Suppl 2:ii1-56. PMC: 3798196. DOI: 10.1093/neuonc/not151. View